These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 22633904

  • 1. RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.
    Kadam RS, Tyagi P, Edelhauser HF, Kompella UB.
    Int J Pharm; 2012 Sep 15; 434(1-2):140-7. PubMed ID: 22633904
    [Abstract] [Full Text] [Related]

  • 2. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration.
    Amrite AC, Edelhauser HF, Singh SR, Kompella UB.
    Mol Vis; 2008 Jan 29; 14():150-60. PubMed ID: 18334929
    [Abstract] [Full Text] [Related]

  • 3. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous.
    Li J, Lan B, Li X, Sun S, Lu P, Cheng L.
    J Control Release; 2016 Dec 10; 243():78-85. PubMed ID: 27717742
    [Abstract] [Full Text] [Related]

  • 4. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
    Sun S, Li J, Li X, Lan B, Zhou S, Meng Y, Cheng L.
    Acta Biomater; 2016 Jun 10; 37():143-54. PubMed ID: 27071973
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of biodegradable controlled release scleral systems of triamcinolone acetonide.
    Blatsios G, Tzimas AS, Mattheolabakis G, Panagi Z, Avgoustakis K, Gartaganis SP.
    Curr Eye Res; 2010 Oct 10; 35(10):916-24. PubMed ID: 20858113
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
    Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J, Csaky KG.
    Exp Eye Res; 2006 Mar 10; 82(3):479-87. PubMed ID: 16168412
    [Abstract] [Full Text] [Related]

  • 12. Improved anti-inflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide.
    Sabzevari A, Adibkia K, Hashemi H, De Geest BG, Mohsenzadeh N, Atyabi F, Ghahremani MH, Khoshayand MR, Dinarvand R.
    Invest Ophthalmol Vis Sci; 2013 Aug 15; 54(8):5520-6. PubMed ID: 23833065
    [Abstract] [Full Text] [Related]

  • 13. Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularization.
    Onami H, Nagai N, Kaji H, Nishizawa M, Sato Y, Osumi N, Nakazawa T, Abe T.
    PLoS One; 2013 Aug 15; 8(3):e58580. PubMed ID: 23472209
    [Abstract] [Full Text] [Related]

  • 14. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model.
    Xu J, Wang Y, Li Y, Yang X, Zhang P, Hou H, Shi Y, Song C.
    J Ocul Pharmacol Ther; 2007 Dec 15; 23(6):527-40. PubMed ID: 18001232
    [Abstract] [Full Text] [Related]

  • 15. Triamcinolone acetonide-loaded PLA/PEG-PDL microparticles for effective intra-articular delivery: synthesis, optimization, in vitro and in vivo evaluation.
    Abou-ElNour M, Ishak RAH, Tiboni M, Bonacucina G, Cespi M, Casettari L, Soliman ME, Geneidi AS.
    J Control Release; 2019 Sep 10; 309():125-144. PubMed ID: 31344425
    [Abstract] [Full Text] [Related]

  • 16. Controlled non-invasive iontophoretic delivery of triamcinolone acetonide amino acid ester prodrugs into the posterior segment of the eye.
    Santer V, Chen Y, Kalia YN.
    Eur J Pharm Biopharm; 2018 Nov 10; 132():157-167. PubMed ID: 30266666
    [Abstract] [Full Text] [Related]

  • 17. The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide.
    Du W, Sun S, Xu Y, Li J, Zhao C, Lan B, Chen H, Cheng L.
    J Ocul Pharmacol Ther; 2013 Sep 10; 29(7):633-8. PubMed ID: 23597073
    [Abstract] [Full Text] [Related]

  • 18. Effect of eye pigmentation on transscleral drug delivery.
    Cheruvu NP, Amrite AC, Kompella UB.
    Invest Ophthalmol Vis Sci; 2008 Jan 10; 49(1):333-41. PubMed ID: 18172110
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of choroidal neovascularization by intravitreal ketorolac.
    Kim SJ, Toma HS.
    Arch Ophthalmol; 2010 May 10; 128(5):596-600. PubMed ID: 20457981
    [Abstract] [Full Text] [Related]

  • 20. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization.
    Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S.
    Arch Ophthalmol; 2009 Mar 10; 127(3):275-81. PubMed ID: 19273790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.